Natalia Szałaj

1. SZAŁAJ, Natalia, BAJDA, Marek, DUDEK, Katarzyna, BRUS, Boris, GOBEC, Stanislav, MALAWSKA, Barbara. Multiple ligands targeting cholinesterases and b-amyloid : synthesis, biological evaluation of heterodimeric compounds with benzylamine pharmacophore. Archiv der pharmazie. 2015, vol. 348, iss. 8, str. 556-563. ISSN 0365-6233. http://onlinelibrary.wiley.com/doi/10.1002/ardp.201500117/abstract, DOI: 10.1002/ardp.201500117. [COBISS.SI-ID 3868785]

2. SZAŁAJ, Natalia, BAJDA, Marek, BRUS, Boris, GOBEC, Stanislav, MALAWSKA, Barbara. Synthesis and biological evaluation of new donepezil-based benzylamine derivatives as multiple ligands targeting cholinesterases and amyloid beta. V: 5th Meeting of the Paul Ehrlich MedChem Euro-PhD Network, July 3-5, 2015, Kraków, Poland. [S. l.: s. n.], 2015. Str. 23, ilustr. [COBISS.SI-ID 4068721]

3. DGACHI, Youssef, ISMAILI, Lhassane, KNEZ, Damijan, BENCHEKROUN, Mohamed, MARTIN, Hélène, SZAŁAJ, Natalia, WEHLE, Sarah, BAUTISTA-AGUILERA, Oscar M., LUZET, Vincent, BONNET, Alexandre, MALAWSKA, Barbara, GOBEC, Stanislav, CHIOUA, Mourad, DRECKER, Michael, CHABCHOUB, Fakher, MARCO-CONTELLES, José. Synthesis and biological assessment of racemic benzochromenopyrimidinimines as antioxidant, cholinesterase, and ▫$ [Aß1-42]$▫ aggregation Inhibitors for Alzheimer's disease therapy. ChemMedChem : Chemistry Enabling Drug Discovery. [Print ed.]. 2016, vol. 11, iss. 12, str. 1318-1327, graf. prikazi. ISSN 1860-7179. http://onlinelibrary.wiley.com/doi/10.1002/cmdc.201500539/abstract, DOI: 10.1002/cmdc.201500539. [COBISS.SI-ID 4022897]

4. HEBDA, Michalina, BAJDA, Marek, WIĘCKOWSKA, Anna, SZAŁAJ, Natalia, PASIEKA, Anna, PANEK, Dawid, GODYŃ, Justyna, WICHUR, Tomasz, KNEZ, Damijan, GOBEC, Stanislav, MALAWSKA, Barbara. Synthesis, molecular modelling and biological evaluation of novel heterodimeric, multiple ligands targeting cholinesterases and amyloid beta. Molecules. 2016, vol. 21, iss. 4, str. 1-24, ilustr. ISSN 1420-3049. http://www.mdpi.com/1420-3049/21/4/410, Repozitorij Univerze v Ljubljani – RUL, DOI: 10.3390/molecules21040410. [COBISS.SI-ID 4051313]

5. PANEK, Dawid, PASIEKA, Anna, SZAŁAJ, Natalia, GODYŃ, Justyna, JOŃCZYK, Jakub, KNEZ, Damijan, WIĘCKOWSKA, Anna, BAJDA, Marek, GOBEC, Stanislav, MALAWSKA, Barbara. Beta-secretase and butyrylcholinesterase inhibitors as potential multi-targeted ligands against Alzheimer's disease. V: Book of abstracts : Joint Symposium on Medicinal Chemistry Frontiers. [S. l.]: [s. n.], 2019. Str. 177, ilustr. https://www.medchemfrontiers.org/programme. [COBISS.SI-ID 4733297]

6. PASIEKA, Anna, PANEK, Dawid, SZAŁAJ, Natalia, GODYŃ, Justyna, JOŃCZYK, Jakub, TABOR, J., KNEZ, Damijan, WIĘCKOWSKA, Anna, BAJDA, Marek, GOBEC, Stanislav, MALAWSKA, Barbara. Novel 1-amino-4-phenylbutan-2-ol derivatives as multifunctional ligands inhibiting butyrylcholinesterase and beta-secretase. V: KRÁTKÝ, Martin (ur.), ZITKO, Jan (ur.), NENCKA, Radim (ur.). New molecules : towards the Drugs of the Future - selected papers from JMMC 2019 : final progamme. Basel: MDPI AG, 2019. 1 str. Biomolecules. ISSN 2218-273X. https://guarant.eu/jmmc2019/files/jmmc-2019-final-programme.pdf. [COBISS.SI-ID 4751985]

7. SZAŁAJ, Natalia, GODYŃ, Justyna, JOŃCZYK, Jakub, PASIEKA, Anna, PANEK, Dawid, WICHUR, Tomasz, WIĘCKOWSKI, Krzysztof, ZARĘBA, Paula, BAJDA, Marek, PIŠLAR, Anja, MALAWSKA, Barbara, SABATÉ, Raimon, WIĘCKOWSKA, Anna. Multidirectional in vitro and in cellulo studies as a tool for identification of multi-target-directed ligands aiming at symptoms and causes of Alzheimer's disease. Journal of enzyme inhibition and medicinal chemistry. 2020, vol. 35, iss. 1, str. 1944-1952, ilustr. ISSN 1475-6374. https://www.tandfonline.com/doi/full/10.1080/14756366.2020.1835882, DOI: 10.1080/14756366.2020.1835882. [COBISS.SI-ID 36188163]
projekt: financer: Slovenian Research Agency

8. MALAWSKA, Barbara, PANEK, Dawid, PASIEKA, Anna, WICHUR, Tomasz, JOŃCZYK, Jakub, GODYŃ, Justyna, WIĘCKOWSKA, Anna, SZAŁAJ, Natalia, BAJDA, Marek, KNEZ, Damijan, GOBEC, Stanislav, SABATÉ, Raimon. Multifunctional anti-Alzheimer's agents with anti-aggregating properties targeting neurotoxic beta-amyloid peptide and Tau protein. V: COST ACTION CA15135 : final status of WG activities within the MuTaLig COST Action : book of the abstracts. Fourth WG Meeting CA15135, Ege University, Faculty of Pharmacy, Bornova, İzmir, Pearl of the Aegean March 5th - 6th 2020. [S. l.: s. n. ], 2020. Str. 48. http://www.mutalig.eu/2019/12/4th-wg-meeting-final-status-of-wg-activities-within-the-mutalig-cost-action-ege-university-izmir-turkey-march-5th-6th-2020/. [COBISS.SI-ID 4900721]

9. PASIEKA, Anna, PANEK, Dawid, JOŃCZYK, Jakub, GODYŃ, Justyna, SZAŁAJ, Natalia, LATACZ, Gniewomir, TABOR, Julia, MEZEIOVA, Eva, KNEZ, Damijan, GOBEC, Stanislav, et al. Discovery of multifunctional anti-Alzheimer's agents with a unique mechanism of action including inhibition of the enzyme butyrylcholinesterase and [gamma]-aminobutyric acid transporters. European journal of medicinal chemistry. [Print ed.]. 2021, vol. 218, str. 1-24, ilustr. ISSN 0223-5234. https://www.sciencedirect.com/science/article/pii/S0223523421002464#!, DOI: 10.1016/j.ejmech.2021.113397. [COBISS.SI-ID 58066947]

10. BAUTISTA-AGUILERA, Oscar M., MANIK, Aleksandra, DIEZ-IRIEPA, Daniel, SZAŁAJ, Natalia, ZARĘBA, Paula, WIĘCKOWSKA, Anna, ŽMUDZKI, Paweł, HONKISZ-ORZECHOWSKA, Ewelina, KNEZ, Damijan, GOBEC, Stanislav, et al. N-Methyl-N-((1-methyl-5-(3-(piperidin-1-yl)propoxy)-1H-benzo[d]imidazol-2-yl)methyl)prop-2-yn-1-amine (MBA-159), a new multitarget small molecule for the therapy of Alzheimer’s disease. Biomedicine & pharmacotherapy. [Print ed.]. 2025, vol. 192, [article no.] 118603, str. 1-17, graf. prikazi. ISSN 0753-3322. https://www.sciencedirect.com/science/article/pii/S0753332225007978, DOI: 10.1016/j.biopha.2025.118603. [COBISS.SI-ID 252870403]
projekt: II thanks AEI (Government of Spain; Grant PID2019–105813RB-C22). JMC thanks AEI (Government of Spain; Grant PID2019–105813RB-C21) and UCJC [Grant: “In vivo analysis of new analogues of Contilisant (MITOPI) (2022)”] for support. This study was also supported by the Ministerio de Economía, Industria y Competitividad (Agencia Estatal de Investigación, AEI; to CGF, and MP) and Fondo Europeo de Desarrollo Regional (MINECO-FEDER) (PID2022–139016OA-I00, PDC2022–133441-I00, to CGF, and MP), Generalitat de Catalunya (2021 SGR 00357; to CGF and MP). This study was co-financed by Secretaria d’Universitats i Recerca del Departament d’Empresa i Coneixement de la Generalitat de Catalunya 2022 (Producte 0092; Llavor 005 and 007; to CGF). The Government of Catalonia (2021 SGR 00357 to C.G.-F and M.P.). II and OMBA thank Laura Contreras and Cristina García for their collaboration. II and OMBA thank subsidies for the implementation of the research program within the framework of the recovery, transformation and resilience plan – financed by the European Union – Next Generation EU. CAM. K.S. and E.H.-O. thank JUMC for support (Grant N42/DBS/000290 and N42/DBS/000332). ADMET studies were financed by the National Science Centre Poland (Grant No. 2019/34/E/NZ7/00090). The ADMET research/study were carried out with the use of research infrastructure co-financed by the Smart Growth Operational Programme POIR 4.2 project no. POIR.04.02.00–00-D023/20. The financial support from the Slovenian Research and Innovation Agency (Research Core Funding grant P1–0208) is gratefully acknowledged. This research was supported by the Ministry of Education, Science, and Sport (MIZŠ) and the European Regional Development Fund OP20.05187 RI-SI-EATRIS. BMA, VGH, CTS and GTD, thanks UAH CEA and CEMAETA CAI for the in vivo pharmacokinetics studies which were carried out with the use of their research infrastructure.